UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000002162
Receipt number R000002647
Scientific Title A Phase I Study of Concurrent Chemotherapy using TS-1 with Involved Field Radiotherapy for Elderly Patients with Non-Small Cell Lung Cancer.
Date of disclosure of the study information 2009/07/03
Last modified on 2009/07/03 17:18:50

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Phase I Study of Concurrent Chemotherapy using TS-1 with Involved Field Radiotherapy for Elderly Patients with Non-Small Cell Lung Cancer.

Acronym

A Phase I Study of Concurrent Chemotherapy using TS-1 with Involved Field Radiotherapy for Elderly Patients with Non-Small Cell Lung Cancer.(HTCARP-0001)

Scientific Title

A Phase I Study of Concurrent Chemotherapy using TS-1 with Involved Field Radiotherapy for Elderly Patients with Non-Small Cell Lung Cancer.

Scientific Title:Acronym

A Phase I Study of Concurrent Chemotherapy using TS-1 with Involved Field Radiotherapy for Elderly Patients with Non-Small Cell Lung Cancer.(HTCARP-0001)

Region

Japan


Condition

Condition

Non-Small Cell Lung Cancer

Classification by specialty

Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To determine maximum tolerated dose and recommended dose of TS-1+RT for elderly patients of Non-small cell lung cancer.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase I


Assessment

Primary outcomes

To determine maximum tolerated dose and recommended dose of TS-1+RT for elderly patients of Non-small cell lung cancer.

Key secondary outcomes

Adverse events for treatment (56days) or after 56days, Response rate (RR), Overall survival (OS), Disease control rate, Disease free survival (DFS)


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Radiation: using 6-10MV X-ray, daily 2Gy, 5 days/week until 64Gy.
TS-1: TS-1 (each level) is administered orally on days 1-14 every 21 days.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

75 years-old <=

Age-upper limit

89 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Histologically confirmed Non-small cell lung cancer
2) Measurable disease
3) Stage II-IIIB
4) Performance Status (ECOG) 0-2
5) more than 75 years old
6) never treatment for Non-small cell lung cancer
7) Adequate organ functions
8) Oral intake is possible
9) Written informed consent

Key exclusion criteria

1 patient with marked fever and suspected infection
2 patient has dreaded complication
3 concomittant active malignancy
4 needing teratment pleulal effusion and hydroperitoneum syndrome
5 patient of the pericardium water retension syndrome
6 patient has chicken pox
7 Serious neuropathy
8 Anarmnesis of drug allergy
9 Severe bone marrow suppression
10 serious renal function disturbance
11 serious liver function disturbance
12 taking other fluoropyrimidime
13 Under treatment with flucytosine
14 Not suitable for participating in the study for any othe reason

Target sample size

18


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yasushi Nagata

Organization

Hiroshima university

Division name

Department of Radiology

Zip code


Address

1-2-3,kasumi, minami-ku, Hiroshima-shi, Hiroshima 730-8551, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Hiroshima university

Division name

Department of Radiology

Zip code


Address


TEL

082-257-1545

Homepage URL


Email



Sponsor or person

Institute

Hiroshima Radiation Oncology Study Group

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 07 Month 03 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Date of protocol fixation

2009 Year 04 Month 01 Day

Date of IRB


Anticipated trial start date

2009 Year 04 Month 01 Day

Last follow-up date

2013 Year 03 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 07 Month 03 Day

Last modified on

2009 Year 07 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002647


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name